Japan university reveals more claims of fabricated drug data

July 31, 2013

A Japanese university Wednesday said it would retract a study that touted the effectiveness of a blood pressure drug made by Swiss pharmaceutical giant Novartis because it was based on fabricated data.

The move was the latest chapter in a growing scandal over allegations that bogus data were used in a string of Japanese university studies for the drug Valsartan which exaggerated its effectiveness in preventing strokes and angina.

On Wednesday, Tokyo's Jikei University School of Medicine said it would retract research that appeared in respected medical journal The Lancet six years ago.

"We will report the conclusions of our investigation to Lancet so the study can be withdrawn," a university spokesman told AFP.

The school's probe concluded that the research, led by one of Jikei's professors, relied on data analysis by an unnamed former Novartis employee, who was also involved in at least one other school's research which has been thrown into question.

The fresh allegations come less than two weeks after Japan's said it was very likely that tests for Valsartan were based on incomplete clinical data.

Jikei University's probe also found it had received about $85,000 worth of grants from Novartis for the study, pointing to a , it said.

The local unit of Novartis could not be immediately reached for comment Wednesday.

On Monday, Yoshiyasu Ninomiya, head of the Swiss firm's Japanese unit, apologised for the involvement of an employee in university studies.

But he stood by other tests that said Valsartan is effective at preventing strokes and angina, as well as controlling .

Novartis sells the drug under the name Diovan in Japan, where it is one of the most commonly prescribed drugs on the market. It is licensed for use in more than 100 countries.

Three other Japanese universities are investigating similar claims, local media reported.

Explore further: Novartis lifts sales outlook despite Q2 profit dip

Related Stories

Novartis lifts sales outlook despite Q2 profit dip

July 17, 2013
(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

October 24, 2012
Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

Novartis posts profit gain thanks to new drugs (Update)

April 24, 2013
(AP)—Swiss pharmaceutical company Novartis AG reported a 6.7 percent increase in profit for the first quarter Wednesday, boosted by new products and emerging markets.

Britain snubs costly Novartis blood cancer drug

February 13, 2013
British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Novartis insists its flu vaccines are safe

October 25, 2012
Swiss pharmaceutical giant Novartis insisted early Thursday that its flu vaccines were safe despite a sales ban by Italy, Switzerland and Austria.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.